# Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

> **NCT07709585** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou University of Traditional Chinese Medicine** · enrollment: 124 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer (NSCLC)
- EGFR Exon 19 Deletion Mutation
- EGFR Exon 21 Mutation
- EGFR Exon 21 L858R Mutation

## Interventions

- **DRUG:** Befotinib
- **DRUG:** Pemetrexed + Cisplatin /Carboplatin

## Key facts

- **NCT ID:** NCT07709585
- **Lead sponsor:** Guangzhou University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-05
- **Primary completion:** 2030-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709585, "Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*